Compare Bristol-Myers Squibb Co (BMY) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Rocket Lab USA Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.46 (market cap $116.30B), while Rocket Lab USA Inc trades at $76.47 (market cap $49.24B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.4× Rocket Lab USA Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Rocket Lab USA Inc pays none. Which is the better fit depends on your goals.
| BMY | RKLB | |
|---|---|---|
Market Cap | $116.30B | $49.24B |
Sector | Health | Technology |
52-Week High | $62.37 | $150.23 |
52-Week Low | $42.60 | $39.48 |
Enterprise Value | $152.24B | $48.00B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Rocket Lab (RKLB) trades at $76.73, down 5.32% over 24 hours, testing key support near $75 amid a bearish technical trend. The company reported Q1 2026 EPS of -$0.02, beating expectations, while revenue reached $601.80M in 2025 with a net loss of -$198.21M. Analyst sentiment remains bullish with a $119.10 consensus price target, supported by recent strategic moves like the Iridium acquisition announced July 13, 2026.
The outlook hinges on execution of growth initiatives and path to profitability, with risks including high cash burn and competitive pressures. Upside potential exists if operational efficiencies improve and satellite revenue scales, but investors face volatility from negative margins and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
